BIOMEDICA

SAFETY DATA SHEET

1. Identification

Product identifier Monoclonal Antibody Anti-Human Factor VIII IgG

Other means of identification

Product code ESH-8, Monoclonal Antibody Anti-Human Factor VIII IgG

Recommended use Research use only.

Recommended restrictions Use in accordance with supplier's recommendations.

Manufacturer/Importer/Supplier/Distributor information

Corporate Headquarters BioMedica Diagnostics Inc.

94 Wentworth Road, PO Box 1030 Windsor, Nova Scotia CANADA BON 2T0

7 cbHJWhdYfgcb Corporate Phone: 1-902-798-5105

Corporate Fax: 1-902-798-1025

Email: info@biomedicadiagnostics.com Website: www.biomedicadiagnostics.com

9a Yf[YbWnHY Yd\ cbY

Bi a VYfg

US, Canada, Puerto Rico & Virgin Islands 1-800-255-3924

International +1-813-248-0585 Australia 1-300-954-583
Brazil 0-800-591-6042 China 400-120-0751
India 000-800-100-4086 Mexico 01-800-099-0731

7 cblf UWibi a VYf MIS9591327

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Not classified.

OSHA defined hazards Not classified.

Label elements

Hazard symbol None.

Signal word None.

Hazard statement None.

Precautionary statement

Prevention Observe good laboratory hygiene practices.

Response Wash with plenty of water.

Storage Store away from incompatible materials.

Disposal Dispose of waste and residues in accordance with local authority requirements.

Hazard(s) not otherwise

classified (HNOC)

None known.

3. Composition/information on ingredients

Mixtures

Chemical name	CAS number	%
Sodium chloride	7647-14-5	20 -< 30
Sodium phosphate dibasic anhydrous	7558-79-4	3 - < 5

Composition comments All concentrations are in percent by weight unless ingredient is a gas. Gas concentrations are in

percent by volume.

4. First-aid measures

Inhalation Move to fresh air. If breathing is difficult, give oxygen. Get medical attention if any discomfort

continues.

Monoclonal Antibody Anti-Human Factor VIII IgG

926518 Version #: 02 Revision date: 31-July-2017 Issue date: 01-December-2017

1 / 6

For skin contact flush with large amounts of water while removing contaminated clothing. Get Skin contact

medical attention if irritation develops and persists.

In case of contact, immediately flush eyes with fresh water for at least 15 minutes while holding the Eye contact

eyelids open. Remove contact lenses if worn. Get medical attention if irritation persists.

Ingestion Rinse mouth thoroughly if dust is ingested. Get medical advice/attention if you feel unwell.

Most important

symptoms/effects, acute and

delayed

Dust may cause eye, skin and respiratory tract irritation.

Indication of immediate medical attention and special

treatment needed

Provide general supportive measures and treat symptomatically.

General information

Ensure that medical personnel are aware of the material(s) involved, and take precautions to

protect themselves.

5. Fire-fighting measures

Suitable extinguishing media

Water spray, carbon dioxide, dry chemical or alcohol-resistant foam.

Unsuitable extinguishing

media

None known.

Specific hazards arising from the chemical

Special protective equipment and precautions for firefighters Hydrogen chloride gas. Sodium oxides.

Selection of respiratory protection for firefighting: follow the general fire precautions indicated in the workplace. Self-contained breathing apparatus and full protective clothing must be worn in

case of fire.

Fire fighting

equipment/instructions

Use standard firefighting procedures and consider the hazards of other involved materials.

General fire hazards No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

No special precautions are necessary beyond normal good hygiene practices. See Section 8 of the SDS for additional personal protection advice when handling this product.

Methods and materials for containment and cleaning up

Avoid dust formation. Sweep or scoop up and remove.

Environmental precautions Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling Avoid prolonged exposure. Avoid contact with skin and eyes.

Conditions for safe storage, including any incompatibilities

Store in a cool, dry, well-ventilated place. Store in a closed container away from incompatible

materials.

8. Exposure controls/personal protection

Occupational exposure limits No exposure limits noted for ingredient(s).

Biological limit values

Appropriate engineering

controls

No biological exposure limits noted for the ingredient(s).

Individual protection measures, such as personal protective equipment

Eye/face protection Wear dust-resistant safety goggles.

Skin protection

Hand protection It is a good industrial hygiene practice to minimize skin contact. Chemical resistant gloves are

recommended.

Other It is a good industrial hygiene practice to minimize skin contact.

No special ventilation requirements.

In case of inadequate ventilation or risk of inhalation of dust, use suitable respiratory equipment Respiratory protection

with particle filter.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

Monoclonal Antibody Anti-Human Factor VIII IgG

9. Physical and chemical properties

Appearance White powder.

Physical state Solid.
Form Powder.
Color Not available.
Odor threshold Not available.

pH 7.4

Melting point/freezing point Not available.

Initial boiling point and boiling Not available.

range

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

(%)

Vapor pressureNot available.Vapor densityNot available.Relative densityNot available.

Solubility(ies)

Solubility (water) Water soluble.

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperature Not available.

Decomposition temperature Not available.

Viscosity Not available.

10. Stability and reactivity

ReactivityThe product is stable and non reactive under normal conditions of storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No data available.

Conditions to avoid Keep away from heat.

Incompatible materials Strong oxidizing agents. Strong acids.

Hazardous decomposition Carbon oxides.

products

11. Toxicological information

Information on likely routes of exposure

Inhalation Dust may irritate respiratory system.

Skin contact Dust may irritate skin.

Eye contact Dust in the eyes will cause irritation.

Ingestion May cause discomfort if swallowed.

Symptoms related to the physical, chemical and toxicological characteristics

Mechanical irritation of skin, eyes and respiratory system.

Information on toxicological effects

Acute toxicity May cause discomfort if swallowed.

Monoclonal Antibody Anti-Human Factor VIII IgG SDS US

Components Species Test Results

Sodium chloride (CAS 7647-14-5)

Acute

Dermal

LD50 Rabbit > 10000 mg/kg

Oral

LD50 Rat > 3980 mg/kg

Other

LD50 Mouse 2602 mg/kg

Skin corrosion/irritation

Dust may irritate skin.

Serious eye damage/eye

Dust may irritate the eyes.

irritation

Respiratory or skin sensitization

Respiratory sensitization Not classified.

Skin sensitization Not classified.

Germ cell mutagenicity Not classified.

Carcinogenicity Not classified.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

Reproductive toxicity Not classified.

Specific target organ toxicity - Not classified.

single exposure

Specific target organ toxicity -

repeated exposure

Not classified.

Aspiration hazard Not classified.

12. Ecological information

Ecotoxicity

Components Species Test Results

Sodium chloride (CAS 7647-14-5)

Aquatic

Crustacea EC50 Water flea (Daphnia magna) 874 mg/l, 48 hours

Persistence and degradability

Bioaccumulative potential

Mobility in soil

No data available.

Not available.

Mobility in general The product is soluble in water.

Other adverse effects No data available.

13. Disposal considerations

Disposal instructions Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Contaminated

instruments and surfaces should be disinfected in accordance with your employer's

chemical-specific and universal/standard precautions.

Hazardous waste code The waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Waste from residues / unused

products

Dispose in accordance with all applicable regulations.

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Not

Not applicable.

Annex II of MARPOL 73/78 and

the IBC Code

15. Regulatory information

US federal regulations

This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard

Communication Standard, 29 CFR 1910.1200.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

CERCLA Hazardous Substance List (40 CFR 302.4)

Sodium phosphate dibasic anhydrous (CAS 7558-79-4) LISTED

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - No

Delayed Hazard - No Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous

No

chemical

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

Not regulated.

(SDWA)

US state regulationsThis product does not contain a chemical known to the State of California to cause cancer, birth

defects or other reproductive harm.

US. Massachusetts RTK - Substance List

Sodium phosphate dibasic anhydrous (CAS 7558-79-4)

US. New Jersey Worker and Community Right-to-Know Act

Sodium phosphate dibasic anhydrous (CAS 7558-79-4)

US. Pennsylvania Worker and Community Right-to-Know Law

Sodium phosphate dibasic anhydrous (CAS 7558-79-4)

US. Rhode Island RTK

Sodium phosphate dibasic anhydrous (CAS 7558-79-4)

US. California Proposition 65

Not Listed.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	Yes
Canada	Domestic Substances List (DSL)	Yes
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	Yes
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	Yes

Country(s) or region Inventory name On inventory (yes/no)* Europe European List of Notified Chemical Substances (ELINCS) Inventory of Existing and New Chemical Substances (ENCS) Japan Yes Existing Chemicals List (ECL) Korea Yes New Zealand New Zealand Inventory Yes **Philippines** Philippine Inventory of Chemicals and Chemical Substances Yes

(PICCS) Toxic Substances Control Act (TSCA) Inventory

Yes

*A "Yes" indicates this product complies with the inventory requirements administered by the governing country(s).

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

Issue date 01-December-2017 **Revision date** 31-July-2017

Version # 02

United States & Puerto Rico

NFPA ratings



Disclaimer

The information above is provided in good faith. It is believed to be accurate and represents the best information currently available to us. HOWEVER, WE MAKE NO WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OF ANY OTHER TYPE, EXPRESSED OR IMPLIED, WITH RESPECT TO PRODUCTS DESCRIBED OR DATA OR INFORMATION PROVIDED, AND WE ASSUME NO LIABILITY RESULTING FROM THE USE OF SUCH PRODUCTS, DATA OR INFORMATION. Users should make their own investigations to determine the suitability of the information for their particular purposes, and the user assumes all risk arising from their use of the material. The user is required to comply with all laws and regulations relating to the purchase, use, storage and disposal of the material, and must be familiar with and follow generally accepted safe handling procedures. In no event shall BioMedica Diagnostics be liable for any claims, losses, or damages of any individual or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if BioMedica Diagnostics has been advised of the possibility of such damages.

SDS US Monoclonal Antibody Anti-Human Factor VIII IgG 6/6 926518 Version #: 02 Revision date: 31-July-2017 Issue date: 01-December-2017